Economic evaluation of an Australian nurse home visiting programme: a randomised trial at 3 years.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
06 12 2021
Historique:
entrez: 7 12 2021
pubmed: 8 12 2021
medline: 8 3 2022
Statut: epublish

Résumé

To investigate the additional programme cost and cost-effectiveness of 'right@home' Nurse Home Visiting (NHV) programme in relation to improving maternal and child outcomes at child age 3 years compared with usual care. A cost-utility analysis from a government-as-payer perspective alongside a randomised trial of NHV over 3-year period. Costs and quality-adjusted life-years (QALYs) were discounted at 5%. Analysis used an intention-to-treat approach with multiple imputation. The right@home was implemented from 2013 in Victoria and Tasmania states of Australia, as a primary care service for pregnant women, delivered until child age 2 years. 722 pregnant Australian women experiencing adversity received NHV (n=363) or usual care (clinic visits) (n=359). First, a cost-consequences analysis to compare the additional costs of NHV over usual care, accounting for any reduced costs of service use, and impacts on all maternal and child outcomes assessed at 3 years. Second, cost-utility analysis from a government-as-payer perspective compared additional costs to maternal QALYs to express cost-effectiveness in terms of additional cost per additional QALY gained. When compared with usual care at child age 3 years, the right@home intervention cost $A7685 extra per woman (95% CI $A7006 to $A8364) and generated 0.01 more QALYs (95% CI -0.01 to 0.02). The probability of right@home being cost-effective by child age 3 years is less than 20%, at a willingness-to-pay threshold of $A50 000 per QALY. Benefits of NHV to parenting at 2 years and maternal health and well-being at 3 years translate into marginal maternal QALY gains. Like previous cost-effectiveness results for NHV programmes, right@home is not cost-effective at 3 years. Given the relatively high up-front costs of NHV, long-term follow-up is needed to assess the accrual of health and economic benefits over time. ISRCTN89962120.

Identifiants

pubmed: 34873002
pii: bmjopen-2021-052156
doi: 10.1136/bmjopen-2021-052156
pmc: PMC8650480
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e052156

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: The 'right@home' sustained nurse home visiting trial is a research collaboration between the Australian Research Alliance for Children and Youth (ARACY); the Translational Research and Social Innovation (TReSI) Group at Western Sydney University; and the Centre for Community Child Health (CCCH), which is a department of The Royal Children's Hospital and a research group of Murdoch Children’s Research Institute. Ownership of the right@home implementation and support licence, which is purchased by Australian state governments for roll out, is shared between institutes.

Références

Infant Ment Health J. 2006 Jan;27(1):5-25
pubmed: 28640426
Health Econ. 2018 Nov;27(11):1684-1698
pubmed: 29968290
Health Promot Chronic Dis Prev Can. 2015 Oct-Nov;35(8-9):151-9
pubmed: 26605564
J Health Soc Behav. 1995 Mar;36(1):1-10
pubmed: 7738325
J Public Health (Oxf). 2009 Sep;31(3):423-33
pubmed: 19497944
BMJ Open. 2017 Mar 20;7(3):e013307
pubmed: 28320789
PLoS One. 2015 Nov 10;10(11):e0142495
pubmed: 26554839
Midwifery. 2018 Oct;65:72-81
pubmed: 29980362
Br Med Bull. 2015 Sep;115(1):19-44
pubmed: 26224694
J Eval Clin Pract. 2017 Dec;23(6):1367-1374
pubmed: 28799197
Qual Life Res. 2016 Dec;25(12):3209-3219
pubmed: 27344318
Ann N Y Acad Sci. 2018 May;1419(1):141-159
pubmed: 29791738
Pediatrics. 2019 Jan;143(1):
pubmed: 30591616
Med Care. 1993 Feb;31(2):155-74
pubmed: 8433578
Pharmacoeconomics. 2018 Jul;36(7):745-758
pubmed: 29779120
Pharmacoeconomics. 2018 Feb;36(2):239-252
pubmed: 29273843
Prev Sci. 2016 Jan;17(1):40-51
pubmed: 26103919
BMJ. 2004 Nov 20;329(7476):1233-6
pubmed: 15550430
Pharmacoeconomics. 2001;19(11):1103-9
pubmed: 11735677
PLoS One. 2015 Apr 01;10(4):e0120182
pubmed: 25830242
Lancet. 2016 Jan 9;387(10014):146-55
pubmed: 26474809
Rand Health Q. 2018 Mar 30;7(4):6
pubmed: 30083418

Auteurs

Shalika Bohingamu Mudiyanselage (S)

School of Health and Social Development, Deakin University, Burwood, VIC, 3125, Australia shalika.b@deakin.edu.au.

Anna M H Price (AMH)

Population Health, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia.
Centre for Community Child Health, The Royal Children's Hospital, Parkville, VIC, 3052, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052, Australia.

Fiona K Mensah (FK)

Population Health, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052, Australia.

Hannah E Bryson (HE)

Population Health, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia.
Centre for Community Child Health, The Royal Children's Hospital, Parkville, VIC, 3052, Australia.

Susan Perlen (S)

Population Health, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia.
Centre for Community Child Health, The Royal Children's Hospital, Parkville, VIC, 3052, Australia.

Francesca Orsini (F)

Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, 3052, Australia.
Melbourne Children's Trials Centre, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, VIC, 3052, Australia.

Harriet Hiscock (H)

Centre for Community Child Health, The Royal Children's Hospital, Parkville, VIC, 3052, Australia.

Penelope Dakin (P)

Australian Research Alliance for Children and Youth, Canberra City, ACT, 2601, Australia.

Diana Harris (D)

Australian Research Alliance for Children and Youth, Canberra City, ACT, 2601, Australia.

Kristy Noble (K)

Australian Research Alliance for Children and Youth, Canberra City, ACT, 2601, Australia.

Tracey Bruce (T)

Ingham Institute, Western Sydney University, Penrith, NSW, 2751, Australia.

Lynn Kemp (L)

Ingham Institute, Western Sydney University, Penrith, NSW, 2751, Australia.

Sharon Goldfeld (S)

Population Health, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia.
Centre for Community Child Health, The Royal Children's Hospital, Parkville, VIC, 3052, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052, Australia.

Lisa Gold (L)

School of Health and Social Development, Deakin University, Burwood, VIC, 3125, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH